Suzanne Lentzsch

Dr. Suzanne Lentzsch is Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University. For over two decades, she has led clinical and translational research efforts focused on novel therapies for multiple myeloma and AL amyloidosis.

Her pioneering work led to the first-in-human trial of Cael-101, a monoclonal antibody targeting amyloid fibrils. Dr. Lentzsch co-founded Caelum Biosciences to advance the therapy, and the company was later acquired by AstraZeneca. This project exemplifies her ability to translate scientific discoveries into impactful treatments.

In multiple myeloma, she has defined novel mechanisms of bone disease, immune suppression, and oncogenic signaling, leading to clinical trials involving venetoclax and bendamustine. Her research is supported by continuous NIH, LLS, IMS, and CRI funding.

Dr. Lentzsch co-chairs the NCI Myeloma Steering Committee and the International Myeloma Society (IMS) Career Development Committee, where she co-created the IMS Career Development Award. She is passionate about mentoring the next generation of translational scientists.

She serves on the ASH Scientific Committee for Plasma Cell Neoplasia, the ASCO Hematologic Malignancies Program Committee, the SOHO and SWOG Myeloma Working Groups, and on the Scientific Advisory Boards of the MMRF, IMS and Nexcella, Inc. She is Associate Editor for JCO and on the Editorial Board of Blood Cancer Discoveries.

Dr. Lentzsch has published over 180 papers in journals such as Nature Communications, JCI, Blood, Leukemia, and JCO, and remains committed to advancing global standards of care and research for plasma cell disorders.